Superb Microvascular Imaging (SMI) and Two-Dimensional Endoscopic Ultrasound Guided Shear Wave Elastography (2D-SWE-EUS) in Differential Diagnosis of Pancreatic Adenocarcinoma (PA) From Other Pancreatic Solid Lesions (PSLs) and Pancreatic neuroendocrinE Tumors (pNETs) Malignancy
NCT07274657 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150
Last updated 2025-12-10
Summary
Pancreatic adenocarcinoma (PA) is the most common tumor of the pancreas. Given its poor prognosis and the major therapeutic consequences, the discrimination between PA and other pancreatic solid lesions is mandatory.
Endoscopic ultrasound (EUS) is admitted as the most sensitive imaging procedure for the detection and characterization of pancreatic tumors. Over the past 30 years, EUS-guided tissue acquisition (EUS-TA), or more recently fine needle biopsy (EUS-FNB), has demonstrated its efficiency for tissue sampling and remains the gold standard for the pathologic diagnosis of pancreatic lesions.
The assessment of pancreatic tumor enhancement using ultrasound contrast agents (UCAs) in real time with imaging specific methods seems useful to improve their characterization either by contrast-enhanced EUS (CE-EUS) or, more recently, by contrast-harmonic EUS (CH-EUS). CH-EUS was already demonstrated useful to differentiate pancreatic adenocarcinoma from other pancreatic lesions.
EUS-Elastography (EUS-E) is another EUS image enhancement technique, which rational based on the difference in elasticity between the tissues. There are two types of elastographies: strain elastography (SE) and shear wave elastography (SWE). SE has proved useful for the characterization of pancreatic lesions and lymph nodes. However, this technique was demonstrated difficult to perform with adequate accuracy and reproducibility for pancreatic lesions and have many limitations. In some recent publications SWE was demonstrated moderate reliability.
Pancreatic neuroendocrine tumors (pNETs) are rare tumors, but according to the last epidemiological data, their incidence and prevalence are steadily rising.
Surgical resection is generally performed for pNETs due to their malignant potential. However, with increasing use of high-resolution conventional imaging, the significant incidence of small (≤ 2 cm) pancreatic neuroendocrine incidentaloma (pNET) has risen in recent decades.
EUS is recognized as the most sensitive procedure for the detection and characterization of pNETs. Overall sensitivity of EUS-TA for the diagnosis of pNETs is high, reaching 95.1% in recently published study, appearing higher in small lesions (≤ 20 mm) than in large lesions (\> 20 mm).
The overall concordance rate for EUS-TA and surgical specimens grading varies from 58% to 86.4% and is higher for lesions ≤ 10 mm, 10-20 mm, comparing to lesions \> 20 mm. These results confirm the risk of under or over-grading of pNETs on the EUS-TA specimen, independently of the needle size which used for the TA.
CH-EUS was also demonstrated accurate in the prediction of pNETs malignancy and useful for decision-making management of these tumors.
Hypothesis
Two new image enhancement EUS technologies were recently developed, able to assess precisely tumor microvascular density and the stiffness of pancreatic lesions, that is correlated to tumor's stroma fibrosis, and thus help to characterize and predict the malignancy, and accordingly, the management of the pancreatic solid lesions. It's particularly useful in overcoming EUS false-negative cases of PA and small pNETs malignancy diagnosis.
Superb Microvascular Imaging (SMI) is a novel doppler technique that enhances the range of visible blood flow, by revealing low velocity microvascular flow, enabling the capture of a higher-quality microvascular flow images. Based on the same principle as CH-EUS, which assesses tumor microvascularization, this technique is expected to be also useful for the PSLs malignancy diagnosis.
Shear Wave Elastography (SWE) relies on the properties of shear-wave propagation to offer an advanced assessment of their velocity
Conditions
- Pancreas Adenocarcinoma (MSI-H)
- Pancreatic Neuroendocrine Tumors (pNET)
Interventions
- DEVICE
-
SMI and 2D-SWE modes
SMI and 2D-SWE are new imaging modes on the new Aplio i800 EUS Unit (Canon Olympus - CE marked)
Sponsors & Collaborators
-
GCS Ramsay Santé pour l'Enseignement et la Recherche
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-01-01
- Primary Completion
- 2028-06-30
- Completion
- 2028-06-30
Countries
- France
Study Locations
More Related Trials
-
Perfusion Assessment With Contrast-Enhanced EUS in Locally Advanced and Metastatic Pancreatic Cancer
NCT03513198 ·Status: UNKNOWN
-
Neoadjuvant Treatment of Resectable or Locally Advanced Borderline Pancreatic Adenocarcinoma: Reproducibility of Tumor Measurement in CT VS MRI
NCT05511116 ·Status: UNKNOWN
-
Comparison Between Base and Cover Slide From Endoscopic Ultrasound Guided Fine Needle Aspiration for Pancreatic Cancer
NCT02190071 ·Status: COMPLETED
-
Diagnosis and Survival Prediction of Pancreatic Cancer by Machine Learning of Image Data
NCT05313854 ·Status: UNKNOWN
-
Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions
NCT03486327 ·Status: TERMINATED ·Phase: PHASE2
-
Contrast Enhanced EUS in the Evaluation of Pancreatic Cancer and Pancreatic Masses
NCT01703026 ·Status: COMPLETED
-
An Ultrasound Imaging Technique to Measure Tumors in People With Pancreatic Ductal Adenocarcinoma (PDAC) or Gastrointestinal (GI) Adenocarcinoma
NCT04837833 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer
NCT01015820 ·Status: COMPLETED ·Phase: NA
-
Radiomics Based on Multimodal Imaging in Predicting Staging and Prognosis of Pancreatic Cancer
NCT04954378 ·Status: COMPLETED
-
Assessment of the Prognosis of Pancreatic Cancer Patients Using 3D MRE
NCT06849063 ·Status: RECRUITING
-
PAncreas Borderline and Locally Advanced Snapshot Study
NCT05470738 ·Status: UNKNOWN
-
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
NCT05723107 ·Status: RECRUITING ·Phase: PHASE1
-
The LINFU® U.S. Registry for the Detection of Asymptomatic Pancreatic Ductal Adenocarcinoma
NCT06157671 ·Status: ENROLLING_BY_INVITATION
-
Repeated EUS-guided Fine Needle Biopsy of Pancreatic Masses After Non-diagnostic or Inconclusive Results
NCT05226572 ·Status: COMPLETED
-
Contrast Enhanced Endoscopic Ultrasound for Vascular Involvement in Pancreatic Lesions
NCT01526590 ·Status: WITHDRAWN ·Phase: NA
-
Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer
NCT07117045 ·Status: RECRUITING
-
Nonfunctioning Small (≤2 cm) Neuroendocrine Pancreatic Incidentaloma
NCT03022188 ·Status: ACTIVE_NOT_RECRUITING
-
Early Screening of Pancreatic Lesions : Development of New Imaging Tools
NCT04007640 ·Status: UNKNOWN ·Phase: NA
-
Clinical Research on a Novel Deep-learning Based System in Pancreatic Endoscopic Ultrasound Scanning
NCT05792267 ·Status: RECRUITING ·Phase: NA
-
The LINFU® U.S. Registry in Patients With Clinical Signs and/or Symptoms of Disease
NCT06276738 ·Status: NOT_YET_RECRUITING
-
Radiographic Response to Chemotherapy in Unresected Localized Pancreatic Cancer
NCT05729737 ·Status: RECRUITING
-
Diffusion MRI for Pancreatic Adenocarcinoma
NCT02896946 ·Status: COMPLETED ·Phase: NA
-
A Study of Chemoradiotherapy Using Gem Plus Nab-paclitaxel for Pancreatic Cancer
NCT02272738 ·Status: COMPLETED ·Phase: PHASE1
-
Minimally Invasive Detection of Lymphatic Micrometastases in Pancreatic Cancer
NCT00826982 ·Status: COMPLETED
-
Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas
NCT04275557 ·Status: RECRUITING